ADLM 2026: YHLO Brings Proven Lab Automation to the Americas

The ADLM 2026 kicked off on July 28 at the Anaheim Convention Center in California, running through July 30.

ADLM is one of the largest and most influential academic events in global clinical laboratory medicine, bringing together thousands of industry experts and decision-makers each year as a key platform for cutting-edge achievements.

This year, YHLO, as an IVD company with over 10 years of consecutive participation, showcased its innovative products and academic achievements.

Throughout the three-day exhibition, the YHLO booth remained highly popular, with a steady stream of professional visitors. The team engaged in in-depth discussions with many industry partners. Live product demonstrations and technical Q&A sessions received enthusiastic feedback, with customers showing great interest in the performance of YHLO's intelligent laboratory automation solutions in space utilization and workflow automation.

During the exhibition, YHLO highlighted its intelligent laboratory solutions, including the iTLA Max and the iTLA mini Plus. This marked the official debut of YHLO's intelligent laboratory automation systems in the Americas market.

As a full-scenario smart ecosystem solution for medium-to-large laboratories, the iTLA Max deeply integrates AI, visual recognition, and automation technologies, providing a full-process automation solution from sample reception, testing, and analysis to report output. The system achieves a balanced throughput of up to 1,300 samples per hour, and is equipped with the iCube intelligent information management system. It has already been installed in many large tertiary hospitals in China.

As a flexible automation solution for small-to-medium laboratories and specific scenarios, the iTLA mini Plus inherits YHLO's consistent philosophy of high integration, intelligence, and efficiency in automation systems, achieving full-process automation coverage with a compact design.

The joint presentation of the iTLA Max and iTLA mini Plus highlighted YHLO's comprehensive automation portfolio, underscoring its differentiated approach to serving laboratories of varying sizes and throughput needs.

For a long time, YHLO has been driven by academic innovation, continuously increasing R&D investment in key specialty areas such as autoimmunity, reproductive health, diabetes, cardiovascular diseases, liver diseases, kidney diseases, and neurological diseases, while promoting the translation of laboratory medicine technology into clinical applications.

At the same time, YHLO actively expands international academic cooperation channels and deeply participates in multinational research projects, having built a global academic cooperation network covering Asia, Europe, and North America.

The successful participation in ADLM 2026 is not only a concentrated display of YHLO's international research achievements but also an important milestone in further deepening its presence in the Americas market and enhancing its global brand influence.

From products to academia, from China to the world, YHLO is steadily advancing, offering more valuable diagnostic solutions to promote the high-quality development of global healthcare.

Adhering to innovation-driven and mutually beneficial cooperation, YHLO aims to advance research in autoimmune and other frontier fields to a higher level, providing better diagnostic and treatment solutions for patients worldwide.

Attachments:

China-Hospeq 2026: YHLO Brings Diagnostic Solutions to Global Health Partners

YHLO at WHX Bangkok 2026: Innovation for Better Diagnostics

China-Hospeq 2026: YHLO Brings Diagnostic Solutions to Global Health Partners

YHLO at WHX Bangkok 2026: Innovation for Better Diagnostics